anZI seizure-free at the last follow up. One hundred and fourteen were followed up for at least three years, 10 for between two and three However, this multivariate model suggested a linear trend in treatment effect from no treatment to six months treatment to 24 months treatment with coding 0, 1, 2 respectively (x2 = 4 7, df = 1, p = 0-031; odds ratio (95% CL): 0 75 (0-58, 098).
Of those who developed status epilepticus in the first week 8% were treated with carbamazepine, 5% with phenytoin and 2% had no treatment. However, the numbers are too small for detailed analysis to discover if there is any treatment effect.
A total of 194 patients (89%) claimed compliance with the treatment policy and 23% of these had seizures within the treatment period (six or 24 months). Twenty three patients (11 %) were non-compliant either because they discontinued treatment on their own initiative or because it was stopped by their physicians. Thirty per cent of such patients suffered seizures. This difference is not statistically significant (odds ratio = 1 31; 95% CL, 0 53, 3-25), but does not exclude important effects for non compliance.
Serum anticonvulsant levels were not monitored in all patients (table 4), and in some patients in whom they were monitored the levels were never in the optimal range, particularly if patients had been randomised to phenytoin. However patients whose anticonvulsant levels were not monitored appeared no more likely to have seizures than those whose levels were (odds ratio = 0 77; 95% CL, 0*39, 
Side effects were relatively common in antiepileptic drug treated patients. The most common side effect necessitating a change or cessation in therapy was acute allergic skin rash. Rashes occurred in 28 and other drugrelated side-effects in 3 of the 217 patients who were treated with antiepileptic drugs. Of these 31 patients, 8 or 25% had seizures which is a lower rate than other groups in the study. A further 6 patients developed signs of drug intoxication.
Discussion
This study confirms that there is a high incidence of postoperative seizures and epilepsy after supratentorial craniotomy for certain nonprogressive pathologies. Previous studies' ' have indicated that the incidence of seizures varies with pathology, being less than 8% in patients with internal carotid artery aneurysms and 38% in patients with middle cerebral artery aneurysms. The presence of haematoma increases the risk in patients with aneurysms to 42%. The overall incidence of seizure or death in this prospective study of high risk patients was 53% by four years (hazard rate (95% CL): 0 19 (0 16, 0 22) per year) compared with a risk of 34% by five years for similar pathologies in a previous retrospective study." The difference may indicate more complete follow up in a prospective study.
North4 advocated prophylactic antiepileptic drugs in patients whose risk of developing postoperative seizures is in excess of 15%. However, a prospective study of 102 patients given prophylactic anticonvulsant drugs did not suggest an important reduction in the incidence of seizures when compared with historical controls.2We therefore included a no treatment control group in this prospective study.
There was a trend for antiepileptic drugs to reduce the incidence of postoperative seizures and epilepsy during the time that they were taken. This reduction was small being on average less than 10% but the confidence limits are such that a reduction of 20% (table 3) could not be ruled out. We found minimal differences between no treatment and treatment with phenytoin or carbamazepine for six months. Patients treated with these drugs for two years appeared to have a somewhat better outcome. Surprisingly some difference was apparent in this group by six months despite the treatment policy not differing from that experienced by patients randomised to treatment for six months. At four years the difference between the two treatment policies is small (1%) though again the confidence limits are too wide to exclude a 15% difference. To reduce the confidence limits, a larger multicentre trial in high risk patients would be needed. North et al3 suggested that phenytoin when given prophylactically was effective in reducing the incidence of seizures between 7 and 70 days postoperatively. Our study fails to confirm this finding. A 5% incidence of seizures was found to occur in each of the groups between the second and thirteenth postoperative weeks inclusive. Seizures and status epilepticus were not reduced within the first week postoperatively by either anticonvulsant drug.
A number of factors appeared to affect the incidence of seizures/death. The pathology was of major importance with the highest risk in patients with meningiomas (75% by four years), an intermediate risk for anterior and middle cerebral aneurysms (51% by four years) and the lowest risk for pituitary tumours (21% by four years). Operative factors also influenced the risk of seizures. Longer operations and those associated with dissection of the lesion away from the surface of the brain were most likely to be complicated by seizures. It appeared that left sided lesions and operations were more likely to be complicated by epilepsy.
The small and uncertain effect of antiepileptic drug treatment in this study might be related to non-compliance and failure to achieve optimal blood levels. Some patients admitted to non-compliance for a variety of reasons. These patients were no more likely to have seizures than those who claimed to be compliant. We did not achieve our objective of detailed blood level monitoring throughout the antiepileptic drug treatment. Of those blood levels available a significant proportion of phenytoin levels were suboptimal and it could be argued that more rigorous monitoring might improve results. However, satisfactory carbamazepine levels were achieved whenever these were monitored. As there was little difference between the outcome for phenytoin or carbamazepine it is doubtful that more rigorous blood level monitoring would have achieved better results unless phenytoin has a greater prophylactic action than carbamazepine, which seems unlikely. This study was pragmatic in its objectives and the compliance and ability to obtain blood level monitoring reflects what is likely to be achieved in routine clinical practice in a group of patients who have undergone craniotomy and had not previously suffered seizures.
The study can be criticised becaused the no treatment group was recruited only in the latter part of the study. However, we have no evidence that characteristics of patients recruited in the 2 phases of the study differed, or that the incidence of seizures or death altered in randomised treatment groups during the course of the study. It is doubtful that this influenced our results. Any treatment effects due to anticonvulsant drugs in this population of patients were achieved at the cost of side effects, particularly allergic skin rashes.8 This study provides little evidence to support the routine use of prophylactic antiepileptic drugs and there is no evidence that prophylactic treatment made epilepsy easier to control with antiepileptic drugs once it developed. The proportion of patients continuing to have seizures during the last year or two years of follow up was not influenced by whether they had taken early treatment. Such seizures continued to be a problem for a high percentage of the patients who have any seizures following craniotomy. In this study the occurrence of seizures and epilepsy is determined by the pathology and the nature of the preoperative brain injury and not to a major degree by effects of antiepileptic drugs on the process of epileptogenesis. These results are similar to those reported by Temkin et a19 in a large randomised study of phenytoin head injured patients.
We cannot therefore recommend prophylactic anticonvulsant drugs after supratentorial craniotomy and would recommend that treatment should be delayed, at least until the occurrence of the first seizure after surgery.
